171 related articles for article (PubMed ID: 34676158)
1. Prognostic Signatures of Alternative Splicing Events in Esophageal Carcinoma Based on TCGA Splice-Seq Data.
Ye P; Yang Y; Zhang L; Zheng G
Front Oncol; 2021; 11():658262. PubMed ID: 34676158
[TBL] [Abstract][Full Text] [Related]
2. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
3. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
Liu Y; Jia W; Li J; Zhu H; Yu J
Front Oncol; 2020; 10():587343. PubMed ID: 33117720
[No Abstract] [Full Text] [Related]
4. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
Zhang D; Zou D; Deng Y; Yang L
J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
[TBL] [Abstract][Full Text] [Related]
5. Development of a Nomogram With Alternative Splicing Signatures for Predicting the Prognosis of Glioblastoma: A Study Based on Large-Scale Sequencing Data.
Wang Z; Gao L; Guo X; Feng C; Lian W; Deng K; Xing B
Front Oncol; 2020; 10():1257. PubMed ID: 32793502
[No Abstract] [Full Text] [Related]
6. Role of alternative splicing events in endometrial cancer prognosis.
Liu J; Mi C; Long W; Sun T
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 46(7):680-688. PubMed ID: 34382583
[TBL] [Abstract][Full Text] [Related]
7. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas.
Yang L; He Y; Zhang Z; Wang W
PeerJ; 2019; 7():e8245. PubMed ID: 31844595
[TBL] [Abstract][Full Text] [Related]
8. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data.
Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS
Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810
[TBL] [Abstract][Full Text] [Related]
9. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
10. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
12. Whole Genome Analysis and Prognostic Model Construction Based on Alternative Splicing Events in Endometrial Cancer.
Wang C; Zheng M; Wang S; Nie X; Guo Q; Gao L; Li X; Qi Y; Liu J; Lin B
Biomed Res Int; 2019; 2019():2686875. PubMed ID: 31355251
[TBL] [Abstract][Full Text] [Related]
13. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
15. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
Front Genet; 2020; 11():534. PubMed ID: 32595697
[TBL] [Abstract][Full Text] [Related]
16. Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma.
Sun JR; Kong CF; Lou YN; Yu R; Qu XK; Jia LQ
Front Genet; 2020; 11():796. PubMed ID: 32793288
[TBL] [Abstract][Full Text] [Related]
17. Identification of Prognostic and Metastatic Alternative Splicing Signatures in Kidney Renal Clear Cell Carcinoma.
Meng T; Huang R; Zeng Z; Huang Z; Yin H; Jiao C; Yan P; Hu P; Zhu X; Li Z; Song D; Zhang J; Cheng L
Front Bioeng Biotechnol; 2019; 7():270. PubMed ID: 31681747
[No Abstract] [Full Text] [Related]
18. Prognostic Value and Potential Role of Alternative mRNA Splicing Events in Cervical Cancer.
Shao XY; Dong J; Zhang H; Wu YS; Zheng L
Front Genet; 2020; 11():726. PubMed ID: 32793282
[TBL] [Abstract][Full Text] [Related]
19. Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma.
Lin G; Wang H; Wu Y; Wang K; Li G
Front Mol Biosci; 2021; 8():682471. PubMed ID: 34295922
[No Abstract] [Full Text] [Related]
20. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma.
Xing L; Zhang X; Tong D
DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
